# A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

> **NCT05062577** · PHASE2 · WITHDRAWN · sponsor: **Astellas Pharma Global Development, Inc.**

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** ASP8062
- **DRUG:** Placebo ASP8062
- **DRUG:** buprenorphine/naloxone

## Key facts

- **NCT ID:** NCT05062577
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-08
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to corporate strategic considerations
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062577, "A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05062577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*